



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
DAHLQVIST et al.

Serial No. 09/537,710

Filed: March 30, 2000

)  
)  
) Art Unit: 1652  
)  
) Examiner: Kerr  
)  
)  
)

For: A NEW CLASS OF ENZYMES IN THE BIOSYNTHETIC PATHWAY FOR THE  
PRODUCTION OF TRIACYLGLYCEROL AND RECOMBINANT DNA MOLECULES  
ENCODING THESE ENZYMES

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Commissioner of Patents and Trademarks, PO Box  
1450, Alexandria, VA 22313-1450, on:

4/1/04  
Date of Deposit

Daniel Kim  
Person Making Deposit

4/1/04  
Signature  
Date of Signature

Honorable Comm'r. of Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SEQUENCE LISTING

Sir:

In response to the office action dated October 1, 2003, a copy of the Sequence  
Listing in computer readable form is attached hereto. The content of the paper copy of the  
Sequence Listing and the copy of the Sequence Listing in computer form is the same, and  
includes no new matter.

## **IN THE SPECIFICATION**

Delete the sequence listing in the specification and substitute replacement pages 1-29 attached hereto as separate pages.

Amend the paragraph from page 13, line 1 through page 13, line 16 as follows:

Yeast strains and plasmids. The wild type yeast strains used were either FY1679 (*MAT $\alpha$  his3- $\Delta$ 200 leu2- $\Delta$ 1 trp1- $\Delta$ 6 ura3-52*) or W303-1A (*MAT $\alpha$  ADE2-1 can1-100 his3-11, 15 leu2-3, 112 trp 1-1 ura3-1*) (7). The YNR008w::KanMX2 disruption strain FVKT004-04C(AL), which is congenic to FY1679, was obtained from the Euroscarf collection (8). A 2751 bp fragment containing the YNR008w gene with 583 bp of 5' and 183 bp of 3' flanking DNA was amplified from W303-1A genomic DNA using *Taq* polymererese with 5'-TCTCCATCTTCTGCAAAACCT-3' (**SEQ ID NO: 20**) and 5'-CCTGTCAAAAACCTTCTCCTC-3' (**SEQ ID NO: 21**) as primers. The resulting PCR product was purified by agarose gel electrophoresis and cloned into the EcoRV site of pBluescript (pbluescript-pdat). For complementation experiments, the cloned fragment was released from pBluescript by *Hind*III-*Sac*I digestion and then cloned between the *Hind*III and *Sac*I sites of pFL39 (9), thus generating pUS1. For overexpression of the PDAT gene, a 2202 bp *Eco*RI fragment from the pBluscript plasmid which contains only 24 bp of 5' flanking DNA was cloned into the BamHI site of the *GAL1-TPK2* expression vector pJN92(12), thus generating pUS4.

REMARKS

It is believed that by submitting the present amendment and sequence listing diskette, the application now fully complies with the requirements of 37 CFR §§ 1.821-1.825. Favorable action by the examiner is solicited.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11-0345. Please credit any excess fees to such deposit account.

Respectfully submitted,

KEIL & WEINKAUF

A handwritten signature in cursive script, appearing to read "Dan Kim", written in black ink.

Daniel S. Kim

Reg. No. 51,877

1350 Connecticut Ave., N.W.  
Washington, D.C. 20036  
(202)659-0100